论文部分内容阅读
目的:研究用健康人细胞因子诱导的杀伤细胞(CIK细胞)输注前后恶性肿瘤患者外周血细胞免疫功能的变化。方法:分离健康人外周血单个核细胞(PBMC),予rhIFN-γ、rhIL-2、rhIL-1β、CD3单克隆抗体(CD3mAb)诱导CIK细胞,回输至病人体内;比较肿瘤患者用CIK细胞治疗前后PBMC对K562的杀伤活性和外周血T淋巴细胞亚群绝对计数的变化情况。结果:肿瘤患者治疗前PBMC杀伤活性和淋巴细胞亚群绝对计数均低于健康人,治疗后除NK细胞绝对计数未见明显改变外均有所提高,但仍比健康人低。结论:健康人CIK细胞治疗能提高肿瘤患者自身抗肿瘤能力。
Objective: To study the changes of cellular immune function in peripheral blood of malignant tumor patients before and after infusion of cytokine-induced killer cells (CIK cells). Methods: Peripheral blood mononuclear cells (PBMCs) from healthy people were isolated and CIK cells were induced by rhIFN-γ, rhIL-2, rhIL-1β and CD3 monoclonal antibodies (CD3mAb) K562 cytotoxic activity of PBMCs before and after treatment and changes of peripheral blood T lymphocyte subsets absolute counts. Results: The killing activity of PBMCs and the absolute count of lymphocyte subsets in cancer patients before treatment were all lower than those in healthy people. After treatment, the absolute count of NK cells increased but remained lower than that of healthy people. Conclusion: CIK cell therapy in healthy human patients can improve their own anti-tumor ability.